Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2026)

Sarepta Therapeutics has reported Finished Goods for 11 years, with the latest figure at $56.2 million in Q2 2026.

• On a quarterly basis, Finished Goods fell 20.86% year-over-year to $56.2 million in Q2 2026; TTM through Jun 2026 was $56.2 million, a 20.86% decrease from a year earlier, with the FY2025 full-year figure at $65.3 million, up 38.36% from the prior year.
• Finished Goods was $56.2 million for Q2 2026 at Sarepta Therapeutics, down from $58.0 million in the prior quarter.
• The five-year high for Finished Goods was $78.0 million in Q3 2024, with the low at $33.9 million in Q1 2022.
• Average Finished Goods over 5 years is $52.8 million, with a median of $51.1 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Finished Goods jumped 83.58% in 2022, then declined 23.62% in 2024.
• Over 5 years, Finished Goods stood at $38.1 million in 2022, then soared by 62.02% to $61.8 million in 2023, then slipped by 23.62% to $47.2 million in 2024, then jumped by 38.36% to $65.3 million in 2025, then slipped by 14.0% to $56.2 million in 2026.
• The last three Finished Goods figures came in at $56.2 million (Q2 2026), $58.0 million (Q1 2026), and $65.3 million (Q4 2025), per Business Quant data.